Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9
Patent disclosure · 2023
- What the patent describes
- Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
- Reported evidence
- The patent describes the NT-3 mimetic series underlying GTS-301 and GTS-302. Patent examples may overlap with later publications and are not independent clinical evidence.
Composite withdrawal index · Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures · Relative to active control; nonmonotonic dose pattern retained
Reported patent results
Reported findings
GTS-302 reduced the composite withdrawal index while several individual signs and general activity remained unchanged.
Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
Population or model Corrected NT-3-mimetic patent containing several preclinical models; selected findings concern GTS-302 in a mouse withdrawal model.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Composite withdrawal index | Reported reductions of 26.9%, 41.4% and 36.5% across three tested exposures | Relative to active control; nonmonotonic dose pattern retained |
| Neutral signs | No significant changes in general motor activity, rearing, grooming or several listed withdrawal signs | Not every component improved |
Animal withdrawal scores do not establish treatment of human dependence. Values are specific to GTS-302 and cannot be assigned to all NT-3 mimetics.
Source for these results ↗ · Reviewed 2026-11-06
Patent claims and provenance
Molecule. Corrected publication describing dimeric NT-3 peptide mimetics; proposed disease indications are not demonstrated human efficacy.
A patent disclosure is not clinical proof, marketing approval or a legal opinion. Related publications and patent family members may describe the same experiments.
- Publication
- RU2800369C9 ↗ · 2023-10-04
- Earliest priority / filing
- Not established / 2022-04-05
- Original applicant / assignee
- Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- Grouping identifier unavailable · family publications are related filings, not independent studies.
Original title, inventors and related publications
Dimeric dipeptide mimetics of neurotrofin-3
Inventors: Сергей Борисович Середенин; Татьяна Александровна Гудашева; Юлия Венеровна Вахитова; Полина Юрьевна Поварнина; Татьяна Алексеевна Антипова; Лариса Геннадьевна Колик; Нелля Михайловна Сазонова; Алексей Валерьевич Тарасюк; Дмитрий Михайлович Никифоров; Лиана Фанзилевна Зайнуллина; Марк Анатольевич Константинопольский; Светлана Сергеевна Ягубова; Рита Ушеровна Островская; Сергей Владимирович Николаев; Илья Олегович Логвинов.
Study limitations and source details
Study limitations
- Patent claims are not evidence of approved clinical uses.
- Some publications describe shared experiments or have corrections.
Source details
Selected original-source text checked; full methodological review pending.
Selected reported results and source limitations reviewed; not a complete risk-of-bias or experimental audit.
Sources checked
Citation
Author unconfirmed. Dimeric dipeptide mimetics of neurotrophin-3 — RU2800369C9 Primary source linked above